Clinical Edge Journal Scan

RA: Lower swollen joint count at 5 years is a predictor of unacceptable pain


 

Key clinical point: Almost one-third of patients with new-onset rheumatoid arthritis (RA) had long-lasting unacceptable pain. Patients with a less inflammatory disease at baseline, in the form of lower swollen joint count (SJC), were at an increased risk for unacceptable pain at 5 years.

Major finding: Almost 49.1% of patients had unacceptable pain at inclusion, which decreased to 30.1% during the first year and remained unchanged thereafter. At 5 years, lower SJC (adjusted odds ratio [aOR] per standard deviation, 0.61; P = .01) was a significant predictor of unacceptable pain.

Study details: The data come from an inception cohort of 232 patients with early RA with symptom duration of at least 12 months.

Disclosures: This work was supported by the Swedish Research Council, the Swedish Rheumatism Association, and Lund University. Some of the authors declared receiving grants, personal fees, and lecture/consulting fees from and/or being an employee of or working as a medical advisor for various sources.

Source: Eberhard A et al. Arthritis Res Ther. 2021 Jun 14. doi: 10.1186/s13075-021-02550-7 .

Recommended Reading

Clinical Edge Commentary: RA July 2021
MDedge Rheumatology
Baricitinib shows long-term promise in treatment-refractory RA
MDedge Rheumatology
Risk for ischemic stroke higher in seropositive RA patients
MDedge Rheumatology
Vertebral fractures still a risk with low-dose oral glucocorticoids for RA
MDedge Rheumatology
COVID-19 vaccine hesitancy still weighs heavy for some rheumatic disease patients
MDedge Rheumatology
Commentary: RA August 2021
MDedge Rheumatology
RA: No significant change in efficacy and safety after adalimumab to CT-P17 switch
MDedge Rheumatology
Bazedoxifene effectively prevents glucocorticoid-induced bone loss in RA
MDedge Rheumatology
RA: Systemic glucocorticoids most beneficial for pain reduction shortly after initiation
MDedge Rheumatology
Sarilumab shows long-term promise in RA refractory to TNF inhibitors
MDedge Rheumatology